Pharmaceuticals News and Research

RSS

NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

National Institute of Standards and Technology researchers at the Institute for Bioscience and Biotechnology Research have demonstrated the most precise method yet to measure the structural configuration of monoclonal antibodies (mAbs), an important factor in determining the safety and efficacy of these biomolecules as medicines.

16 Apr 2015

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

AbbVie today announced that the Japanese Ministry of Health, Labour and Welfare has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir.

16 Apr 2015

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute and its newly created affiliate for the exclusive sales and distribution of the BeneFishial family of products.

15 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

Study: Children with type 1 diabetes five times more likely to be admitted to hospital

Children living with type 1 diabetes are nearly five times more likely to be admitted to hospital than non-diabetic children, a new study (attached) has found.

15 Apr 2015

Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences Ltd. has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund.

15 Apr 2015

Cantab Connect CTIS-Abuse Liability product exceeds $1.5m sales in first 9 months

Cambridge Cognition Holdings plc,the developer of cognitive assessment software, announces that sales of Cantab Connect CTIS-Abuse Liability have exceeded £1m in its first 9 months from launch.

15 Apr 2015

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Small cell lung cancer (SCLC) will be the concentrated focus when 100 global experts in the field meet for a workshop hosted by the International Association for the Study of Lung Cancer on April 22-24, 2015 at Memorial Sloan Kettering Cancer Center in New York City.

15 Apr 2015

Atlas Genetics signs diagnostic collaboration to explore new use of io system

Atlas Genetics Ltd, the ultra-rapid 'test and treat' molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases.

15 Apr 2015

A beginner’s guide to CRISPR genome editing

In a recent DECODED Online entry, Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, provides an overview of the CRISPR/Cas9 system to scientists looking to enhance their genome modification strategy in model organisms or cell lines.

From Integrated DNA Technologies 14 Apr 2015

iCardiac launches industry-first full risk-sharing program for cardiac safety studies

iCardiac Technologies, a market and scientific leader in the conduct of cardiac safety assessments, announced today that it has launched the industry’s first full risk-sharing program for Thorough QT studies. Leveraging its innovative High Precision QT™ methodology for analyzing ECG waveforms, iCardiac’s program guarantees to sponsors that one of two desirable outcomes will be achieved.

14 Apr 2015

Children with type 1 diabetes five times more likely to be admitted to hospital

The number of children being diagnosed with type 1 diabetes is increasing 3-4% every year and more so in school-aged children. Treating the condition is complex and poor management can often lead to medical emergencies that result in hospitalisation, placing ever greater demands on health services

14 Apr 2015

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Hungary.

14 Apr 2015

Clyde Biosciences, a leading drug toxicity testing company, closes Series A investment

Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd.

14 Apr 2015

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

MorphoSys's collaboration with Janssen has resulted in three clinical programs to date, two of which are in phase 2 development and one, guselkumab, in phase 3 in psoriasis (most advanced trial)...

14 Apr 2015

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...

13 Apr 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

A new study finds that effective new hepatitis C drugs are so expensive the state of Rhode Island would have to spend almost twice its entire prison health budget to treat all its chronically infected inmates.

10 Apr 2015

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.

10 Apr 2015

Special concession on PTI training courses for new and growing life science organisations

Following its recent introduction of innovative game-based e-learning modules, Pharmaceutical Training International (PTI) is providing the opportunity to make substantial savings on its full range of training courses to start-ups and SMEs (with fewer than 50 employees), as well as non-profit organisations and government bodies...

From Pharmaceutical Training International 10 Apr 2015

Pharmaceuticals News and Research

NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

Pivotal enters into sales, distribution agreement for BeneFishial family of products

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

Study: Children with type 1 diabetes five times more likely to be admitted to hospital

Clyde Biosciences announces £2 million ‘Series A’ investment

Cantab Connect CTIS-Abuse Liability product exceeds $1.5m sales in first 9 months

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Atlas Genetics signs diagnostic collaboration to explore new use of io system

A beginner’s guide to CRISPR genome editing

iCardiac launches industry-first full risk-sharing program for cardiac safety studies

Children with type 1 diabetes five times more likely to be admitted to hospital

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

Clyde Biosciences, a leading drug toxicity testing company, closes Series A investment

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

Special concession on PTI training courses for new and growing life science organisations

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring